CD86 and neoplasm: Based on H-score analysis and differentiation of TME cells by a pathologist, we revealed an increased and notable expression of CD80 and CD86 on tumor and/or TME cells in five patients, a maintained notable expression in one patient, and a decrease into negative expression in two patients following CAR T cell immunotherapy (Figures 1A and 1B).